AOD9604 is a derivative of human growth hormone (hGH) and a modified version of the hGH fragment 176-191 peptide, incorporating a di-sulfide bridge. What’s exciting about this peptide is that it does not affect IGF-1 or insulin levels and is, therefore, not a risk in promoting glucose intolerance. 

BPC-157 5mg, TB-500 (Thymosin Beta-4) 5 mg , GHK-Cu 20 mg
(Total Glow Blend)

The BPC-157, TB-500 (Thymosin Beta-4), and GHK-Cu mix is a mix of three different peptides, measured at 5 mg of BPC-157, 5 mg of TB-500, and 20 mg of GHK-Cu, for a total of 30 mg.

Researchers have been interested in BPC-157, a peptide initially isolated from gastric proteins, because of its ability to promote the growth of blood vessels and healing of injured tissue through a range of cellular mechanisms.

TB-500, a naturally occurring fragment of a larger protein, is typically studied for its ability to migrate cells into injured areas. It encourages the formation of new blood vessels, and reduces inflammation, especially in muscle and connective tissue.

The third ingredient, GHK-Cu, is a low molecular weight copper-binding peptide that has been linked in studies to wound healing, collagen synthesis, and even hair growth stimulation.

Together, these three compounds appear to have an effect on the same biological processes, but with a broader effect than any of them would have in isolation.

For example, TB-500 and BPC-157 both cause the growth of new vessels, while GHK-Cu adds another layer of support by activating the growth of the cells that line blood vessels.

On the structural repair side of tissues, TB-500 enables cell migration by promoting actin activity, while GHK-Cu and BPC-157 both influence fibroblasts and collagen to offer support for stronger connective tissue.

A second point of overlap is in reducing inflammation and oxidative stress, and it may be here that researchers are hopeful for these peptides in longer-term recovery studies.

As a result of these synergistic and shared activities, the blend is being investigated for use in everything ranging from musculoskeletal trauma to wound healing and post-surgical recovery.

CJC-1295 with DAC is a synthetic peptide, analog of the growth hormone-releasing hormone. Though CJC-1295 without DAC has the same effect and stimulates the production and secretion of growth hormone, the addition of Drug Affinity Complex (DAC) is what increases its half-life allowing it to act longer and more potently. 

Research in animals also suggests that CJC-1295 with DAC stimulates insulin-like growth factor 1 (IGF-1) and plays a part in a number of physiological processes.

References: 

1. https://pubmed.ncbi.nlm.nih.gov/16352683/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC2787983/
3. https://academic.oup.com/jcem/article-abstract/91/3/799/2843281?redirectedFrom=fulltext
4. https://www.researchgate.net/publication/7416716_Prolonged_Stimulation_of_Growth_Hormone_GH_and_Insulin-Like_Growth_Factor_I_Secretion_by_CJC-1295_a_Long-Acting_Analog_of_GH-Releasing_Hormone_in_Healthy_Adults

Cagrisema is a potent new blend, a combination that integrates two peptides – cagrilintide and semaglutide.

Semaglutide is a GLP-1 receptor agonist; a version of human GLP-1 hormone, modified to resist the degradation by the enzyme dipeptidyl peptidase-4. 

Cagrilintdide, on the other hand, is an amylin analogue. Its role is to mimic the human hormone amylin and is structurally designed to be resistant to enzymatic degradation.

Together, these two peptides profoundly influence chemical structures and induce hormonal changes:

• Leading to the receptor changes within the pancreas and the brain
• Boosting insulin secretion 
• Interacting with the receptors involved in appetite regulation
• Mimicking the action of amylin
• Decreasing glucagon secretion

All in all, this is a sophisticated, more importantly, incredibly potent combination of two peptides whose actions complement each other. Cagrisema combination influences some key hormonal processes and plays a role in metabolic regulation.